Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25947151 | 0.92 | — | — | |
| SCHEMBL26338964 | 0.81 | CHRM1 (0.46) | MMP8CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL24144847 | 0.77 | CHRM5 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| SCHEMBL25947092 | 0.76 | DNM1 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| SCHEMBL26418131 | 0.72 | MMP8 (0.35) | MMP8CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL25947322 | 0.71 | DNM1 (0.36) | — | |
| SCHEMBL21026914 | 0.70 | — | — | |
| SCHEMBL20706531 | 0.69 | ALDH1A1 (0.34) | — | |
| SCHEMBL19902135 | 0.69 | CHRM1 (0.46) | MMP8CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14157686 | 0.68 | DNM1 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250056-A1 | PROCESS FOR SYNTHESIZING LIPIDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250056-A1 | PROCESS FOR SYNTHESIZING LIPIDS | PLIN1, SREBF1, SREBF2 | MMP8 1533/4885CHRM2 4830/4885CHRM4 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.